Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256084 | 0.95 | TRPA1 (0.46) | TRPA1KMT2AHTTLMNAPOLB | |
| SCHEMBL20011193 | 0.90 | TRPA1 (0.43) | TRPA1KMT2AHTTLMNARXFP1 | |
| SCHEMBL20182456 | 0.84 | TRPA1 (0.42) | TRPA1KMT2AHTTLMNAPOLB | |
| SCHEMBL18255775 | 0.81 | ADORA2B (0.51) | KMT2ALMNARXFP1POLBSMN1; SMN2 | |
| SCHEMBL20182693 | 0.81 | TRPA1 (0.45) | TRPA1HTTLMNAPOLBHIF1A | |
| SCHEMBL18819085 | 0.81 | TRPA1 (0.43) | TRPA1KMT2AHTTRXFP1PARG | |
| SCHEMBL18256053 | 0.78 | TRPA1 (0.44) | TRPA1KMT2AHTTLMNARXFP1 | |
| SCHEMBL20182571 | 0.77 | TRPA1 (0.47) | TRPA1KMT2ARXFP1POLBHIF1A | |
| SCHEMBL18256106 | 0.76 | TRPA1 (0.44) | TRPA1KMT2AHTTLMNARXFP1 | |
| SCHEMBL18256065 | 0.75 | KMT2A (0.64) | KMT2ALMNAALDH1A1RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | TRPA1 2926/4885KMT2A 3576/4885HTT 2349/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | TRPA1 2926/4885KMT2A 3576/4885HTT 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.